Antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates (ADCs) are a highly-targeted type of cancer treatment designed to specifically deliver chemotherapies directly to tumor cells—all while sparing healthy cells. The key to this type of therapy is getting three distinct molecules to work together.
The ADC travels throughout the body until the monoclonal antibody recognizes a tumor cell expressing the targeted antigen. The ADC binds to the cell and is brought inside, where the linker releases the chemotherapy payload, leading to the death of the tumor cell. ADCs, while a proven therapeutic, currently have limited scope—but RemeGen’s therapeutics will expand the class to include the most serious diseases in oncology and beyond.